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Abstract
Objective: To investigate if antenatal glucocorticoid treatment has an effect on hippocampal histology of the human
preterm newborn.
Patients and Methods: Included were consecutive neonates with a gestational age between 24 and 32 weeks, who were
born between 1991 to 2009, who had died within 4 days after delivery and underwent brain autopsy. Excluded were
neonates with congenital malformations and neonates treated postnatally with glucocorticoids. The brains were routinely
fixed, samples of the hippocampus were stained with haematoxylin and eosin and sections were examined for presence or
absence of large and small neurons in regions of the hippocampus. Additional staining with GFAP, neurofilament and
vimentin was performed to evaluate gliosis and myelination. The proliferation marker Ki67 was used to evaluate neuronal
proliferation. Staining with acid fuchsin-thionin was performed to evaluate ischemic damage.
Results: The hippocampi of ten neonates who had been treated with antenatal glucocorticoids showed a lower density of
large neurons (p=0.01) and neurons irrespective of size (p=0.02) as compared to eleven neonates who had not been
treated with glucocorticoids. No difference was found in density of small neurons, in myelination, gliosis, proliferation or
ischemic damage.
Conclusion: We found a significantly lower density of neurons in the hippocampus of neonates after antenatal
glucocorticoid treatment. Although the pathophysiological and clinical interpretations of these findings are not clear, they
are consistent with those from experiments in mice and rhesus monkeys.
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Introduction
Administration of glucocorticoids (GCs) to pregnant women at
risk of preterm birth has led to a major improvement in the
outcome of preterm born neonates. Treatment with antenatal GCs
reduces the risk of neonatal death, respiratory distress syndrome,
periventricular/intraventricular haemorrhage, necrotising entero-
colitis, infectious morbidity, need for respiratory support and
neonatal intensive care unit admission [1]. Betamethasone and
dexamethasone, the synthetic GCs that are given for this
indication, cross the placenta and have a high affinity for the
GC receptors. These receptors are found in most organs including
the brain [2]. GCs promote cellular differentiation at the expense
of proliferation resulting into dose related effects in many different
species [3]. Regarding the brain there is a dose related reduction in
weight in for instance fetal sheep and rat pups [4–6]. In humans, a
reduction of head circumference after multiple antenatal GC
courses has been found in various observational studies [7–9] and
in one out of four recent large randomised controlled trials in
which head circumference was an outcome measurement [10–13].
The effects of GCs on brain cell proliferation are most pronounced
in areas undergoing active growth and differentiation at the
moment of treatment [14]. In this respect, the hippocampal
structure, which is part of the limbic system, plays a crucial role in
cognitive functions such as learning, memory storage, and spatial
orientation and is a metabolic active structure [15,16]. Further-
more, receptors for GCs are highly expressed in the hippocampus
[2]. It is therefore likely that among various brain regions the
hippocampus appears to be the most vulnerable to antenatal GC
treatment. Disturbance in development of the hippocampus may
have effects later in life. In monkeys, multiple doses of
dexamethasone were associated with a dose-dependent decrease
in the number of neurons in the hippocampus as well as
degeneration of neurons in this region [17,18]. A study in mice
using a clinically relevant dose has established a link between
prenatal exposure to dexamethasone and reduced hippocampal
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shortly after treatment [19]. Follow-up at adulthood of offspring
mice who received corticosteroid treatment in utero showed
decreased cell proliferation in the dentate gyrus and adverse effects
on hippocampal function [20].
As far as we know, there are no data on the effects of antenatal
GC therapy on hippocampal histology of the human fetus or
neonate yet. It was our aim to investigate if antenatal GC
treatment affects the histological structure of the hippocampus of
the fetus and the neonate.
Methods
Ethics Statement
The study protocol was approved by The Ethics Committee of
the University Medical Center, Utrecht. They concluded that the
Medical Research Involving Human Subjects Act did not apply
for this study and that the parents of the research subjects didn’t
need to be asked for consent. Anonymous use of redundant tissue
for research purposes is part of the standard treatment agreement
with patients in our hospital.
Population
From a database containing data on all children born in the
University Medical Center, Utrecht, The Netherlands, we
identified consecutive neonates with gestational age between 24
and 32 weeks, born between 1991 to 2009, who died during or
within 4 days after delivery and underwent a brain autopsy after
oral informed consent of the parents. Neonates with congenital
malformations or massive brain destruction, such as massive
cerebral haemorrhage or encephalitis and/or treated with
postnatal GCs were excluded.
We reviewed in retrospect the medical files of the included
neonates and their mothers. We recorded the reason for
admission, use of antenatal GCs, interval between the first gift of
GCs and birth, use of postnatal GCs and other drugs, gestational
age at delivery, route of delivery, birth weight, sex, parity of the
mother, neonatal morbidity, underlying cause and mechanism of
perinatal mortality and the interval between birth and death. A
complete antenatal GC course consisted of two intramuscular
doses of 12 mg betamethasone with a 24-hrs interval. Birth weight
percentiles were calculated using birth weight z-scores. Growth
charts corrected for gestational age, sex and parity according to
the Dutch Perinatal Registry were used to calculate the birth
weight z-scores (http://www.perinatreg.nl) [21]. Weight for GA at
the 50
th percentile was used as the mean of the population and the
average standard deviation (SD) calculated by the formula
[21SD+1SD]/2 was used. Subsequently, the z-score was con-
verted into an exact percentile for each studied subject with a z-
score to percentile web calculator (http://www.measuringusability.
com). Underlying cause and mechanism of perinatal mortality was
based on clinical and pathological findings classified using the Tulip
classification [22].
Histological preparation
Brain tissue was fixed in buffered formalin 4%. Four weeks after
removal, coronal slices were made and embedded in paraffin after
which 3 mm sections were cut and stained with haematoxylin and
eosin (H&E). Subsequently the hippocampus was examined for the
density of large, small and neurons irrespective of size in all four
cornu-ammonal (CA) regions of the hippocampus (CA1, CA2,
CA3 and CA4). The density of large and small neurons was scored
using semiquantitative analysis comparable with the method used
by Groenendaal et al. [23]: high density (4 points), moderate
density (3 points), low density (2 points) or (nearly) absent
(1 point). Density of neurons irrespective of size was scored by:
high (4 points), moderate (3 points), low/moderate (2 points) or
low (1 point).
In order to study possible effects of antenatal GC treatment on
myelination and gliosis, we performed additional staining on 4 mm
sections with antibodies reacting against neurofilament (Monosan,
1:800), vimentin (Dako, 1:400) and glial fibrillary acidic protein
(GFAP, Dako, 1:800) on the hippocampus of 11 of the 21 neonates
(Table S1, numbers 2-5, 7-9,11,14,15,21). The sections were
examined for intensity of staining in all four cornu-ammonal (CA)
regions of the hippocampus (CA1, CA2, CA3 and CA4) and
scored as: high (4), moderate (3), low (2) or (nearly) absent (1).
Proliferative activity of neurons was evaluated using the
proliferation marker Ki67 (Dako, 1:400). The Ki67 protein is
expressed in all proliferating cells in late G1, S, G2 and M phases
of the cell cycle [24]. Sections were examined for the number of
Ki67 positive nuclei in the dentate gyrus and germinal matrix, two
areas where active proliferation usually takes place. The number
of Ki67 positive immunoreactive cells was scored as: high (4),
moderate (3), low (2) or (nearly) absent (1).
To visualise neuronal degeneration and hypoxic ischemic
damage a combined staining procedure, acid fuchsin-thionin
(0.1% fuchsin, Gurr/BDH; 0.25% thionin, Chroma) was used.
Neurons showing ischemic cell change with acidophilic (pink)
cytoplasm and contracted nuclei were regarded as nonviable.
Sections were examined for intensity of staining, markers of acute
ischemia as apoptotic figures and cytotoxic edema in the
hippocampus and scored for every category as: high (4), moderate
(3), low (2) or (nearly) absent (1).
In order to test the hypothesis that small neurons are mature
neurons and large neurons immature neurons, we performed an
additional staining with antibodies reacting against doublecortin
(1:200, Santa Cruz). Doublecortin is a microtubule-associated
protein expressed by neuronal precursor cells and immature
neurons.
An experienced perinatal pathologist who was blinded for the
treatment of GCs and for the other clinical data, performed the
histological examination.
We studied the relation between hippocampal histology and the
use of antenatal GCs. Furthermore, relations between the density
of large, small or neurons irrespective and gestational age at
delivery (#28 weeks versus .28 weeks), birth weight (#1000 grams
versus .1000 grams), obstetrical complications (small for gesta-
tional age (weight,p10), preeclampsia (PE) and/or HELLP versus
other pathology), mode of delivery (vaginal delivery versus
caesarean section (CS)), placenta pathology (small placenta (weight
,p10) with infarcts versus other pathology), signs of inflammation
in the placenta (placenta with chorioamnionitis and/or funisitis
versus no signs of infection in the placenta) and mechanism of death
(respiratory insufficiency versus other pathology) were also
investigated.
Statistical analysis
Clinical characteristics between the groups were compared by
the student t-test or Mann-Whitney U test. Histological data were
analysed using the Mann-Whitney U test. SigmaStat software
(SigmaStat for Windows, Version 2.0) was used for all statistical
analyses. P values ,0.05 were accepted as statistically significant.
Results
A total of twenty-one neonates were included. Eleven neonates
had not received GCs Ten had received a complete course of
Hippocampal Histology after Antenatal Corticoids
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the 21 included neonates are shown. Mean gestational age of the
neonates not treated with GCs (n=11) was 27.1 weeks (SD 2.4
weeks) and of the neonates treated with antenatal GCs (n=10)
28.2 weeks (SD 2.1 weeks; p=0.28). Median birth weight was 610
grams (range 450–1700 g) in the group not treated with GCs, 865
grams (range 475–1985 g) in the group treated antenatal-
ly.(p=0.13). Median birth weight percentile was 10.1 (range
0.1–85) in the group not treated with GCs, 38.6 (range 0.4–80) in
the antenatally treated group (p=0.11). The median interval
between the first dose of antenatal GCs and delivery was 3 days
(range 1–16 days); one neonate had received a repeated course of
GCs before birth (number 17).
With routine H&E staining we examined in all neonates the
presence or absence of large and small neurons in the different
hippocampal regions (Figure 1A–D). The nuclei of large neurons
showed hypochromatic staining and were large. When present,
large neurons showed the highest density in the CA1 region and
density gradually decreased in the CA2, CA3 and CA4 region.
The nuclei of small neurons were small and round and showed a
hyperchromatic staining. When present, small neurons had the
lowest density in CA1 and the density increased gradually in the
CA2, CA3 and CA4 region. We found no relation between the
density of large, small or neurons irrespective of size and
gestational age at delivery (#28 weeks versus .28 weeks), birth
weight (#1000 grams versus .1000 grams), obstetrical complica-
tions (small for gestational age, PE and/or HELLP versus other
pathology), mode of delivery (vaginal delivery versus CS), placenta
pathology (small placenta with infarcts versus other pathology),
signs of inflammation in the placenta (placenta with chorioamni-
onitis and/or funisitis versus no signs of infection in the placenta)
and mechanism of death (respiratory insufficiency versus other
pathology) (Table 1). In hippocampi of neonates treated with
antenatal GCs, we found significantly more often a low density of
large neurons (p=0.01) as compared to hippocampi of neonates
not treated with GCs (Table 1 and 2). No difference in small
neurons was found (p=0.35; Table 1 and 2). When we consider
the density of neurons irrespective of their size, neonates treated
Figure 1. Example of the hippocampus of a patient not treated with GCs and of a patient treated with antenatal GCs. Figure 1A shows
an example of the hippocampus of a patient not treated with GCs (number 6) and 1B of a patient treated with antenatal GCs (number 19). Panel 1C
and 1D represent a magnification of transition zone 2 and zone 3 of panel 1A and 1B. Neuronal density is lower in Figure 1D compared to 1C.
Figure 1A and 1B (206, H&E) and Figure 1C and 1D (2006, H&E).
doi:10.1371/journal.pone.0033369.g001
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in the hippocampus than untreated neonates (p=0.02;Fig. 1C,D,
Table 1 and 2).
The neurofilament and GFAP staining showed the same low
intensity in all hippocampal regions. The intensity of the vimentin
staining was the highest in the CA4 region in all hippocampi. In
one neonate (number 4) the vimentin staining could not be
evaluated because of absence of the hippocampal structure in the
additional sections. Because we found no differences at all between
the first eleven studied cases for the neurofilament, vimentin or
GFAP staining, we terminated this investigation.
We found no differences in the degree of hypoxic ischemic
damage by comparing the presence of apoptotic figures (p=0.27),
degree of cytotoxic edema (p=0.84), intensity of fuchsin stained
neurons (p=0.06), number of Ki67 positive neurons in the dentate
gyrus (p=0.91) and germinal matrix (p=0.75), between the group
treated with antenatal GC and the group not treated with GC
(Fig. 2, Table 3). In one neonate (number 20) the Ki67 staining
could not be evaluated in the germinal matrix and in one neonate
(number 1) the fuchsin staining could not be evaluated in the
hippocampus, both because of absence of these structures in the
additional sections.
Small and large neurons were both doublecortin immunoreac-
tive. In the brains with most severe damage using acid thionin-
fuchsin staining, we detected less doublecortin immunoreactive
neurons, supporting the loss of neurons due to hypoxic ischemic
damage.
Discussion
To our knowledge, this is the first study evaluating the effects of
antenatal GC therapy on the histology of the human hippocampus.
We found a significantly lower density of neurons in the
hippocampus of neonates after antenatal GC treatment
(p=0.02). No effect was found on gliosis or myelination after
antenatal GC therapy in the eleven cases in which this was studied.
A limitation of this study is the heterogenicity of our patient
group. Several pathological conditions during pregnancy, delivery
and early neonatal life may have caused hypoxic ischemic damage
in the fetus or neonate, a condition in which hippocampal
neuronal damage can easily occur. These potentially confounding
effects can only be ruled out in a large cohort study with a
controlled prospective design. However, for obvious reasons it will
not be possible to realise a study with such a design in human
neonates. In our study we tried to minimise confounding factors in
several ways. First, by including only neonates, who lived for a
maximum of four days, limiting influences of early neonatal life.
Furthermore, we compared groups for indicators of recent
Table 1. Density scores according to subgroups of patients characteristics.
Score large neurons p-value Score small neurons p-value
Score neurons
irrespective of size p-value
Antenatal GC treatment
No AGCs 4.0 [3.0–4.0] 0.01 3.0 [1.3–3.0] 0.35 3.0 [3.0–3.8] 0.02
AGCs 2.0 [2.0–3.0] 2.0 [2.0–3.0] 2.5 [2.0–3.0]
GA at delivery
,/=28 weeks 3.0 [2.0–4.0] 0.29 3.0 [2.0–3.0] 0.13 3.0 [3.0–3.5] 0.07
.28 weeks 3.0 [2.0–3.0] 2.0 [1.0–3.0] 3.0 [2.0–3.0]
Birth weight
,/=1000 grams 3.0 [2.0–4.0] 0.19 3.0 [2.0–3.0] 0.27 3.0 [3.0–3.0] 0.10
.1000 grams 2.5 [2.0–3.0] 2.0 [1.0–3.0] 2.5 [2.0–3.0]
Obstetrical complications
SGA, PE and/or HELLP 3.0 [2.0–4.0] 0.68 3.0 [2.0–3.0] 0.18 3.0 [3.0–3.8] 0.09
Other pathology 3.0 [2.0–3.0] 2.0 [2.0–3.0] 3.0 [2.0–3.0]
Mode of delivery
Vaginal delivery 3.0 [2.0–4.0] 0.51 3.0 [2.0–3.0] 0.08 3.0 [2.8–3.0] 0.49
Caesarean section 2.5 [2.0–3.5] 1.5 [1.0–3.0] 3.0 [2.0–3.0]
Placenta pathology
Small placenta (.p10) with infarcts 3.0 [2.0–4.0] 0.78 3.0 [1.3–3.8] 0.56 3.0 [2.3–4.0] 0.30
Other pathology 3.0 [2.0–3.0] 2.0 [2.0–3.0] 3.0 [2.0–3.0]
Signs of inflammation in the
placenta
Chorioamnionitis and/or funisitis 3.0 [3.0–3.3] 0.23 2.5 [2.0–3.0] 0.74 3.0 [3.0–3.0] 1.00
No signs of inflammation 2.0 [2.0–3.8] 2.0 [1.3–3.0] 3.0 [2.0–3.0]
Mechanism of death
Respiratory insufficiency 3.0 [2.0–4.0] 0.68 2.0 [2.0–3.3] 0.60 3.0 [2.8–3.3] 0.38
Other pathology 3.0 [2.0–3.5] 2.5 [1.5–3.0] 3.0 [2.0–3.0]
Numbers represent the median scores, assigned for density of large, small and neurons irrespective of size (see text for details). Between square brackets: p25–p75
range.
Differences are tested with the Mann-Whitney U test.
doi:10.1371/journal.pone.0033369.t001
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highlights neurons with recent hypoxic ischemic damage. No
significant differences were found between the two groups. The
mode of delivery may affect the density of neurons, but there was
no difference in neuronal density between the group born by a
vaginal delivery compared to the group delivered by caesarean
section.
The results of our study are consistent with earlier investigations
using animal models [17–19]. In mice, antenatal dexamethasone
treatment significantly decreased the number of neurons in the CA
regions of the hippocampus directly after treatment until postnatal
day 10 and in the dentate gyrus even till postnatal day 20 [19].
Also in two of the three studies investigating the effect of antenatal
GC treatment on the hippocampus of rhesus monkeys, a
decreased number of pyramidal neurons was found, which was
ascribed to antenatal GC treatment. Beside this, shrunken neurons
with pycnotic nuclei were found in the treated group [17,18]. In
the third study these phenomena were found in the treated as well
as in non-treated animals and the findings could therefore not be
ascribed to the GC treatment [25].
The mechanism behind the decreased neuronal density was not
unveiled in this study. Several animal studies have focused on GC-
induced hippocampal damage, however very few of them have
used clinically relevant doses. Two studies that did use a clinically
relevant dose, mention two possible mechanisms; suppression of
proliferation and/or caspase-3 mediated apoptosis. However these
studies are inconclusive. In 2003 Scheepens et al. [26] published a
study determining the effects of a single course of prenatal
betamethasone (2 doses of 170 mgram/kg) within the rat. They
demonstrated that betamethasone was antiproliferative to brain
cells, including hippocampal cells shortly after treatment for up to
4 days, with some catch-up recovery of the anti-proliferative effects
there-after. No changes in caspase-3 mediated apoptosis were
seen. In contrast Noorlander et al. [19] used a single, somewhat
higher, dose of antenatal dexamethasone (1 dose of 400 mgram/
Table 2. Density of large neurons, small neurons, and
neurons irrespective of size in the hippocampus of 21
neonates.
No GCs
(n=11)
Antenatal
GCs (n=10) p-value
Lage neurons
High 6 0
Moderate 3 4
Low 2 6
(Nearly) absent 0 0 0.01
Small neurons
High 2 0
Moderate 5 3
Low 1 6
(Nearly) absent 3 1 0.35
Neurons irrespective of size
High 3 0
Moderate 7 5
Low/moderate 1 4
Low 0 1 0.02
Numbers represent individual cases.
Differences are tested with the Mann-Whitney U test.
doi:10.1371/journal.pone.0033369.t002
Figure 2. Apoptosis, cytotoxic edema, fuchsin staining and Ki67 positivity in the hippocampus and Ki67 positivity in the germinal
matrix of preterm neonates not treated with antenatal GCs and treated with antenatal GCs. Horizontal axis: the two study groups,
vertical axis: staining score (see text for details). Median values are indicated by horizontal lines. Differences are tested with the Mann- Whitney U test.
doi:10.1371/journal.pone.0033369.g002
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They detected, shortly after treatment, beside a decreased
proliferative activity in the subgranular zone of the dentate gyrus,
the zone where neurogenesis predominantly occurs, increased
caspase-3 apoptotic activity throughout the whole hippocampus.
The precise mechanism behind the anti-proliferative effect of GCs
on the brain are unknown but possibly involve a down regulation
in expression of the trophic growth factors: brain-derived
neurotrophic factor (BDNF), IGF-1 and basic fibroblast growth
factor (bFGF) [27–29]. Furthermore, administration of any of
these three factors has been shown to specifically increase
neurogenesis [30,31]. In our study we found no difference in
proliferative and apoptotic activity between the antenatal treated
group and the control group. An explanation could be that the
time interval between corticosteroid exposure and brain analysis
may have been too long to detect a possible increase in apoptosis.
Another explanation could be that the examined groups were too
small to detect a difference.
There was no evidence of a reduction in myelination in our
study. However since there is very little myelination in the
immature brain between 24 and 32 weeks of gestation, we can not
speculate on the possible effects of GCs on myelination given the
very low gestational age of the neonates studied. Quantification of
myelination at two years of age would be a more appropriate time
to examine the effects of antenatal GCs on myelination.
We observed large and small neuronal cells in the hippocampus
and both cell types showed its own distribution pattern in the
hippocampal regions (large neurons highest density in CA1; small
neurons highest density in CA4). By light microscopic examina-
tion, both cell types appeared to be neurons of the pyramidal layer
of the hippocampus consisting of large and small pyramidal
neurons. Our data showed that perinatal GC treatment has more
effect on the density of large neurons than on the density of small
neurons. We hypothesize that the large neurons might be more
immature neurons and the small neurons mature neurons. To test
this hypothesis we conducted a doublecortin immunoreactive
staining. Both, large and small neurons were doublecortin
immunoreactive. Hence, in our study the pathophysiological
significance of the density of large and small neurons was not
unveiled. Therefore, we also provided the density of all neurons,
irrespective of size, which was also lower in the infants treated with
GCs (Table 2).
The functional consequences of the effects on hippocampal
neuronal density that we observed are unknown. In mice,
decreased cell proliferation after exposure to GCs in utero has
functional consequences like failure in a number of cognitive and
behavioral functions in later life and accelerated aging [20].
However, caution is necessary when extrapolating data from
animal models to the human situation.
A study that compared brainweight of neonates who had been
delivered between 24 and 34 weeks of gestation showed no
significant difference in brain weight between the group that
received single or multiple courses of antenatal GCs and a group
that did not receive GCs [32]. Thus far, long term outcome after
one course of antenatal GCs has been reassuring, and shows only
subtle neurological impairment at the age of 6 [33], but normal
development in terms of physical, intellectual and emotional
development at the age of 12, 20 and 30 years [34–37]. Repeated
courses of antenatal GCs, however, have been associated with
psychomotor delay and hyperactivity in childhood. [38]. More-
over, GC therapy after birth, with higher dosages and prolonged
administration as compared to the antenatal therapy, has been
shown to increase neuro-developmental impairment [39].
In conclusion, in this unique dataset we found a lower density of
neurons in the hippocampus of preterm neonates who were
antenatally treated with GCs. We cannot rule out the fact that the
observation is caused by other factors as well. Determination of a
causal relationship would require a randomized trial. Long-term
effects are hard to predict because effects may be transient and the
plasticity of the brain at this age may perhaps compensate for a
decrease in neurons in the hippocampus. Our observations may
cause concern because of the wide use of GC treatment in the
perinatal period and indicate that more detailed and specific
follow-up studies in humans are required.
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Table 3. Semiquantitative analysis of the degree of apoptosis, cytotoxic edema fuchsin staining and Ki67 positivity in the
hippocampus and of Ki67 positivity in the germinal matrix.
No GCs (n=11) Antenatal GCs (n=10) p-value
Apoptosis 3.0 [2.0–3.0] 2.0 [1.0–3.0] 0.27
Cytotoxic edema 3.0 [2.3–3.0] 3.0 [3.0–3.0] 0.84
Fuchsin staining 3.0 [2.0–3.0]
1 2.0 [2.0–2.0] 0.06
Ki67 staining dentate gyrus 3.0 [2.0–3.0] 2.5 [2.0–3.0] 0.91
Ki67 staining germinal matrix 3.0 [2.3–4.0] 3.0 [2.0–4.0]
2 0.75
Numbers represent the median scores, assigned for high/moderate/low or (nearly) absent and the p25–p75 range between square brackets. Differences are tested with
the Mann-Whitney U test.
1n=10 cases.
2n=9 cases.
doi:10.1371/journal.pone.0033369.t003
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